Although norovirus is a global public health problem, there is no effective remedy or vaccine. Norovirus affects approximately 685 million people each year, with an estimated social cost of $60 billion. According to the Centers for Disease Control and Prevention (CDC), around two hundred million cases are seen in children under the age of five, resulting in around 50,000 child deaths each year, mostly in developing countries. In vitro studies of CDI-988 showed potent broad-spectrum antiviral activity against a panel of GII. 4 norovirus pandemic proteases, which have caused the majority of norovirus outbreaks internationally since 2002, as well as favorable pharmacokinetic actives targeting the gastrointestinal tract.
About COVID-19 COVID-19 hospitalizations have recently increased in the U. S. The new JN. 1 variant is responsible for about 20% of those cases. Driven by the expected emergence of new COVID-19 variants, the global COVID-19 therapy market is expected to exceed $16 billion by the end of 2031. The ability of an asymptomatic user to transmit the infection to another user has increased the public health challenge. CDI-988 showed astonishing in vitro potency against SARS-CoV-2 with sustained activity against variants of concern. By targeting viral replication protease, Cocristal believes it is conceivable to expand an effective remedy against all coronaviruses, adding COVID-19 and its variants, as well as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).
About Seasonal Influenza Each year there are approximately 1 billion cases of seasonal influenza worldwide, with 3-5 million severe illnesses and up to 650,000 deaths, according to the World Health Organization. On average about 8% of the U.S. population contracts influenza each season. In addition to the health risk, influenza is responsible for approximately $10.4 billion in direct costs for hospitalizations and outpatient visits for adults in the U.S. annually.
About Cocrystal Pharma, Inc.Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact: LHAJody Investor Relations Cain310-691-7100jcain@lhai. com
Media Contact: JQA PartnersJules Abraham917-885-7378Jabraham@jqapartners. com
# # #